BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/28/2020 1:45:47 AM | Browse: 639 | Download: 1391
 |
Received |
|
2020-04-30 08:17 |
|
Peer-Review Started |
|
2020-04-30 08:18 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-21 06:07 |
|
Revised |
|
2020-06-01 16:43 |
|
Second Decision |
|
2020-09-07 10:08 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-09-08 00:52 |
|
Articles in Press |
|
2020-09-08 00:52 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-09-12 20:46 |
|
Typeset the Manuscript |
|
2020-09-22 14:40 |
|
Publish the Manuscript Online |
|
2020-09-28 01:45 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Minireviews |
| Article Title |
Liver injury in COVID-19: A minireview
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jian-Nan Zhao, Ying Fan and Shuo-Dong Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ying Fan, MD, PhD, Doctor, Doctor, Professor, Department of General Surgery, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning Province, China. coolingpine78@163.com |
| Key Words |
Liver injury; COVID-19; Novel coronavirus; SARS-CoV-2; Hepatoprotective drugs; Pandemic |
| Core Tip |
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2. Liver injury was observed in COVID-19 patients especially in severe and critical types. Liver injury presented differentially based on disease severity, geographical areas, and patient age. It may be related to systemic inflammatory response, immune damage, ischemia-reperfusion injury, viral direct damage, drug induce, mechanical ventilation, and underlying diseases. Special treatment is not necessary in most mild liver injury cases and only one or two types of hepatoprotective drugs should be used to treat significant liver injury. Monitoring liver function is important parameter during the treatment of COVID-19 as it affects survival and recovery of patients, and its significance should be emphasized for doctors treating the disease. The risk of COVID-19 infection in liver transplantation recipients was not increased. |
| Publish Date |
2020-09-28 01:45 |
| Citation |
Zhao JN, Fan Y, Wu SD. Liver injury in COVID-19: A minireview. World J Clin Cases 2020; 8(19): 4303-4310 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i19/4303.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i19.4303 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
